Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Ipratropium bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropium 40 µg inhalationspulver, kapsel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 40 µg kapsel + inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 250 µg/1 ml inhalationsvæske til nebulisator, opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 500 µg/2 ml inhalationsvæske til nebulisator, opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 20 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 40 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
fenoterolhydrobromid 100 µg + ipratropiumbromid 40 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
salbutamol 100 µg + ipratropiumbromid 20 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
salbutamol 2,5 mg + ipratropiumbromid 500 µg nebulisatorampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
enoterolhydrobromid 500 µg + ipratropiumbromid 1,25 mg nebulisatorampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 18 µg inhalation, inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 0,02 % inhalationsvæske, opløsning, hætteglas a 2,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide 0.03% spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 0,06 % spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 14 g aerosol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
albuterolsulfat 103 µg + ipratropiumbromid 18 µg aerosol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide 167 microgram/mL and salbutamol (as salbutamol sulfate) 833 microgram/mL solution for inhalation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Fenoterol hydrobromide+ipratropium bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Albuterol+ipratropium bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropium 0,03 % vandig næsespray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Albuterol sulfate + ipratropium bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 20 µg indåndingsudløst aerosolinhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
fenoterolhydrobromid 100 µg + ipratropiumbromid 40 µg indåndingsudløst aerosolinhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 20 µg CFC-fri inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
ipratropiumbromid 17 µg HFA-inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide monohydrate (substance) |
Is a |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide anhydrous (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide monohydrate (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide 17 mcg/actuation inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
|
Ipratropium bromide 21 microgram/actuation nasal spray |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 21 microgram/actuation nasal spray |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 20 microgram/actuation pressurized solution for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 20 microgram/actuation pressurized solution for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 40 microgram/actuation pressurized solution for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 40 microgram/actuation pressurized solution for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 42 microgram/actuation nasal spray |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 42 microgram/actuation nasal spray |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely ipratropium bromide 250 microgram/1 milliliter conventional release solution for inhalation (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely ipratropium bromide 250 microgram/1 milliliter conventional release solution for inhalation (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 40 microgram/actuation powder for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 40 microgram/actuation powder for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 167 microgram/mL and salbutamol (as salbutamol sulfate) 833 microgram/mL solution for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Ipratropium bromide 167 microgram/mL and salbutamol (as salbutamol sulfate) 833 microgram/mL solution for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Ipratropium bromide 200 microgram/mL and salbutamol (as salbutamol sulfate) 1 mg/mL solution for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Ipratropium bromide 200 microgram/mL and salbutamol (as salbutamol sulfate) 1 mg/mL solution for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Ipratropium bromide 20 microgram and levosalbutamol (as levosalbutamol sulfate) 50 microgram/actuation pressurised solution for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Ipratropium bromide 20 microgram and levosalbutamol (as levosalbutamol sulfate) 50 microgram/actuation pressurised solution for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely ipratropium bromide 40 microgram and levosalbutamol (as levosalbutamol sulfate) 100 microgram/1 actuation conventional release powder for inhalation (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely ipratropium bromide 40 microgram and levosalbutamol (as levosalbutamol sulfate) 100 microgram/1 actuation conventional release powder for inhalation (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
2 |
Ipratropium bromide 250 microgram/mL solution for nebulizer |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |
Ipratropium bromide 250 microgram/mL solution for nebulizer |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium bromide (substance) |
Inferred relationship |
Some |
1 |